SNF472: Progress towards a novel therapeutic agent for vascular
calcification and calciphylaxis
Abstract
Vascular calcification (VC) is a common complication in chronic kidney
disease (CKD) patients and is strongly associated with the increased
risk of cardiovascular diseases and all-cause mortality. Calciphylaxis
is a rare type of VC with extremely high mortality, characterized by
intense pain and skin damage secondary to systemic arteriolar
calcification, and is most common in patients with CKD. Currently, the
treatment of VC and calciphylaxis in CKD focuses on controlling risk
factors and has made very little progress. SNF472 is a novel VC
inhibitor that has demonstrated outstanding efficacy and safety in
recent clinical trials. This review highlights the current knowledge and
progress of the latest clinical research on SNF472.